Prescription drug · BLA
Hulio (adalimumab-fkjp) NDC 83257-016
Kit · Biocon Biologics Inc
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 83257-016-42 | 83257001642 | 2 TRAY in 1 KIT (83257-016-42) / 1 KIT in 1 TRAY * 2 TRAY in 1 KIT / 1 SYRINGE in 1 TRAY / .4 mL in 1 SYRINGE * 2 PACKET in 1 KIT / 1 mL in 1 PACKETMarketed from Dec 30, 2023 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Hulio
- Generic name (nonproprietary)
- adalimumab-fkjp
- Dosage form
- Kit
- Labeler
- Biocon Biologics Inc
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761154
- Marketing start
- Marketing end
- Identifiers
- Product ID 83257-016_e4767905-1306-0022-2a53-8c5d4b218e2fSPL ID e4767905-1306-0022-2a53-8c5d4b218e2fSPL set ID 661ad70b-c313-2899-8a7e-7a67bd897ca9RxCUI 797544, 2640404, 2640410, 2640412, 2640415, 2640417, 2640418
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- NDC on a medical claim
N483257001642followed by a unit qualifier and the quantityPackage 83257-0016-42. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
HULIO is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. J uvenile Idiopathic Arthritis (JIA) ( 1.2 ) : reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. A nkylosing Spondylitis (AS) ( 1.4 ): reducing signs and …
Excerpt only. Read the full label for complete information.
Other NDCs under BLA 761154
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Adalimumabadalimumab-fkjp | — | Kit | Biocon Biologics Inc | 83257-020 |
| Hulioadalimumab-fkjp | — | Kit | Biocon Biologics Inc | 83257-019 |
| Adalimumabadalimumab-fkjp | — | Kit | Biocon Biologics Inc | 83257-021 |
| Adalimumabadalimumab-fkjp | — | Kit | Biocon Biologics Inc | 83257-022 |